Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.55 |
| ▸ | ATR | Q13535 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961520 | 0.88 | KCNH2 (0.53) | LRRK2ATRKCNH2MTORPIK3CA | |
| SCHEMBL2925588 | 0.88 | LRRK2 (0.56) | LRRK2ATRKCNH2MTORPIK3CA | |
| SCHEMBL2934913 | 0.84 | ATR (0.67) | LRRK2ATRKCNH2 | |
| SCHEMBL2932693 | 0.83 | KCNH2 (0.71) | LRRK2ATRKCNH2 | |
| SCHEMBL2933163 | 0.83 | BRD9 (0.51) | LRRK2MTORCCNE1CDK2GSK3A | |
| SCHEMBL2932858 | 0.78 | KCNH2 (0.58) | LRRK2ATRKCNH2PIK3CAALOX5AP | |
| SCHEMBL2931478 | 0.77 | KCNH2 (0.56) | ATRKCNH2MTORPIK3CAMET | |
| SCHEMBL13515284 | 0.77 | KCNH2 (0.56) | LRRK2ATRKCNH2MTORPIK3CA | |
| SCHEMBL2928695 | 0.77 | KCNH2 (0.55) | LRRK2ATRKCNH2ALOX5APFEN1 | |
| SCHEMBL2927685 | 0.75 | ATR (0.51) | ATRMTORPIK3CAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | LRRK2 309/4885ATR 556/4885KCNH2 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.